Moleculin Biotech, Inc. Profile Avatar - Palmy Investing

Moleculin Biotech, Inc.

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment …

Biotechnology
US, Houston [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Moleculin Biotech, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of MBRX's Analysis
CIK: 1659617 CUSIP: 60855D200 ISIN: US60855D2009 LEI: - UEI: -
Secondary Listings
MBRX has no secondary listings inside our databases.